Skip to content
Drugs Targeting EGFRGabriele Wright2024-02-07T10:50:36-06:00
Drugs Targeting EGFR
- Gilotrif (afatinib) – approved for stage 4 NSCLC patients with a change in EGFR as detected by a biomarker test.
- Iressa (gefitnib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.
- Rybrevant (amivantamab-vmjw) – approved for stage 4 NSCLC with a change in EGFR called exon 20 insertion as detected by a biomarker test.
- Tagrisso (osimertinib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test. Tagrisso is also approved for stage 4 NSCLC patients with the EGFR T790M change.
- Tarceva (erlotinib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test. Tarceva is also approved in combination with Cyramza (ramucirumab) for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.
- Vizimpro (dacomitinib) – approved for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.